Dr Reddy's inks pact with Eli Lilly for Covid drug Baricitinib

Our Bureau | | Updated on: Jul 02, 2021

FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo/File Photo | Photo Credit: Mike Segar

Will allow manufacture and commercialization of the drug

 

Dr. Reddy’s Laboratories Ltd has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Co for the manufacture and commercialization of the drug, Baricitinib, in India.

The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company’s existing range of Covid-19 therapeutics.

“From the start, we have been determined to explore every possible avenue against Covid-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India,'' Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s Laboratories, said in a release on Wednesday.

Published on May 12, 2021
COMMENTS
This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you